Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-jRCT1080222652
JPRN-jRCT1080222652
Unknown
Phase 4

Extension study following the phase I/II clinical study of CT-P13 in the patients with rheumatoid arthritis

ippon Kayaku Co., Ltd.0 sitesNovember 13, 2014
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
ippon Kayaku Co., Ltd.
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 13, 2014
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
ippon Kayaku Co., Ltd.

Eligibility Criteria

Inclusion Criteria

  • •(1\) Patients who have completed final observation after 54\-week administration in the phase I/II clinical study and whose symptoms are stable.
  • •(2\) Patients for whom administration of CT\-P13 is deemed appropriate as of the end of final observation after 54\-week administration in the phase I/II clinical study.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Unknown
Phase 1
Extension study following the phase I/II clinical study of CT-P13 in the patients with rheumatoid arthritisRheumatoid arthritis
JPRN-jRCT2080222369ippon Kayaku Co., Ltd.
Recruiting
Phase 1
ong-Term Follow-up: Phase I/II clinical study to evaluate the safety and efficacy of the infusion of RP-L102Fanconi anemia subtype A (FA-A)MedDRA version: 20.0Level: LLTClassification code: 10055206Term: Fanconi's anemia Class: 10010331Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
CTIS2022-501082-52-00Rocket Pharmaceuticals Inc.14
Active, not recruiting
Phase 1
A study to test how well patients with plaque psoriasis tolerate BI 730357 over a longer period and how effective it isPlaque PsoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
EUCTR2018-003487-31-DEBoehringer Ingelheim Pharma GmbH & Co. KG180
Active, not recruiting
Phase 1
A follow-up study in patients with moderate to severe active ulcerative colitis.Moderate to severe Ulcerative Colitis.MedDRA version: 20.1Level: LLTClassification code 10066678Term: Acute ulcerative colitisSystem Organ Class: 100000004856Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
EUCTR2017-003284-35-PLABIVAX30
Active, not recruiting
Phase 1
A follow-up study in patients with moderate to severe active ulcerative colitis.Moderate to severe Ulcerative Colitis.MedDRA version: 20.1Level: LLTClassification code 10066678Term: Acute ulcerative colitisSystem Organ Class: 100000004856Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
EUCTR2017-003284-35-HUABIVAX30